logo

JP5778735B2 Use of pyrimidine derivatives for the Egfr

If you want to confirm some technical details before you order,
just need to send a message or e-mail: [email protected].
Then our professional sales staff will contact you within 2 hours.

Synthesis and evaluation of novel pyrimidine-based dual .

Synthesis and evaluation of novel pyrimidine-based dual EGFR/Her-2 inhibitors. ... we will report an SAR study of pyrimidine derivatives for EGFR/Her-2 dual inhibitors. ... We use cookies to help provide and enhance our service and tailor content and ads.

WO2009109605A1 - Use of pyrimidine derivatives for the .

The present invention relates to the use of specific pyrimidine derivatives in the treatment of Epidermal Growth Factor Receptor (EGFR) family members (including EGFR1 also known as HER1 or Erb-B1 ; EGFR2 also known as HER2 or Erb-B2; and EGFR3 also known as HER3 or Erb-B3) dependent diseases or diseases that have acquired resistance to agents ...

USE OF PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF EGFR .

The present invention relates to the use of compounds of formula (I) in the treatment of Epidermal Growth Factor Receptor (EGFR) family members dependent diseases or diseases that have acquired resistance to agents that target EGFR family members, use of said compounds for the manufacture of pharmaceutical compositions for the treatment of said ...

US20140161722A1 - Use of pyrimidine derivatives for the .

US20140161722A1 - Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members - Google Patents

Discovery of 2,4,6-trisubstitued pyrido[3,4- d ]pyrimidine .

Targeting acquired drug resistance is the major challenge in the treatment of EGFR-driven non-small cell lung cancer (NSCLC). In this study, a novel class of compounds containing pyrido[3,4-d]pyrimidine scaffold was designed as new generation EGFR-TKIs to overcome this challenge.The most promising compound B30 inhibited HCC827 and H1975 cells growth with the IC 50 values of 0.044 μM and 0.40 ...

Structure-Activity Relationship of Indole-Tethered .

To the best of our knowledge, derivatives of pazopanib that effectively inhibit EGFR have not been reported previously. Herein, we describe the synthesis and evaluation of pyrimidine derivatives that inhibit EGFR while retaining their inhibitory activity for angiokinases, and determined their structure-activity relationship (SAR).

USE OF PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF EGFR .

USE OF PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF EGFR DEPENDENT DISEASES OR DISEASES THAT HAVE ACQUIRED RESISTANCE TO AGENTS THAT TARGET EGFR FAMILY MEMBERS . United States Patent Application 20140161722 . Kind Code: A1 . Abstract: The present invention relates to the use of compounds of formula (I) ...

Use of pyrimidine derivatives for the treatment of egfr .

The present invention relates to the use of compounds of formula (I) in the treatment of Epidermal Growth Factor Receptor (EGFR) family members dependent diseases or diseases that have acquired resistance to agents that target EGFR family members, use of said compounds for the manufacture of pharmaceutical compositions for the treatment of said diseases, combinations of said compounds with ...

Using pyrimidine derivatives for treating egfr-dependent .

The present invention relates to the use of a specific pyrimidine derivatives for the treatment of diseases associated with members of the family of epidermal growth factor (EGFR) (including EGFR1, also known as HER1 or Erb-B1, EGFR2, also known as HER2 or Erb-B2, and EGFR3, known as HER3, or Erb-B3), or diseases with acquired resistance to agents directed against the EGFR family, as well as ...

JP5778735B2 - Use of pyrimidine derivatives for the Egfr .

JP5778735B2 - Use of pyrimidine derivatives for the Egfr dependent diseases or egfr family members to treat diseases that have acquired resistance to agents that target ...

JP5778735B2 - Use of pyrimidine derivatives for the Egfr .

JP5778735B2 - Use of pyrimidine derivatives for the Egfr dependent diseases or egfr family members to treat diseases that have acquired resistance to agents that target ...

USE OF PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF EGFR .

use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members.

WO2009109605A1 - Use of pyrimidine derivatives for the .

The present invention relates to the use of specific pyrimidine derivatives in the treatment of Epidermal Growth Factor Receptor (EGFR) family members (including EGFR1 also known as HER1 or Erb-B1 ; EGFR2 also known as HER2 or Erb-B2; and EGFR3 also known as HER3 or Erb-B3) dependent diseases or diseases that have acquired resistance to agents ...

JP5778735B2 - Use of pyrimidine derivatives for the Egfr .

JP5778735B2 - Use of pyrimidine derivatives for the Egfr dependent diseases or egfr family members to treat diseases that have acquired resistance to agents that target ...